BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Stock Information for BioVie Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVie Inc.

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.